Social phobia
Drug research and approvals for social phobia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 43 studies of social phobia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 43
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Caplyta Versus Placebo for Adults With Social Anxiety DisorderNCT07799493 · Phase 4 · Jason Careri · starts Sep 10, 2026
- Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)Therapy for Social Anxiety DisorderNCT07772401 · Not applicable · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts Sep 5, 2025
- Anxiety Skills StudyNCT07774481 · Not applicable · Ohio State University · starts Oct 20, 2025
- Efficacy of Expectancy Focused Exposure Therapy for Anxiety DisordersNCT07753330 · Not applicable · University of Chile · starts Jul 1, 2026
- Efficacy of Attention Bias Modification vs. Placebo for Social Anxiety DisorderNCT07666776 · Not applicable · Tel Aviv University · starts Jun 15, 2026
- Intermittent Theta Burst Stimulation of the Prefrontal Cortex in Social Anxiety DisorderNCT07466277 · Not applicable · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts Dec 9, 2025
- ACTsocially: The (Dis)Similarities of ACT for Changing Internalizing and Externalizing Symptomatology in AdolescenceNCT07456631 · Not applicable · University of Coimbra · starts Sep 1, 2023
- Metacognitive Therapy Compared to Cognitive-behavioral TherapyNCT07382323 · Not applicable · Karolinska Institutet · starts Jan 28, 2026
- Online Radical Acceptance Intervention for Social Anxiety DisorderNCT07325929 · Not applicable · University of Haifa · starts Dec 16, 2025
Approved 3
- ParoxetineSerotonin transporter inhibitor
- SertralineSerotonin transporter inhibitor
- VenlafaxineSerotonin transporter inhibitor
Phase 3 6
- Fasedienol
- QuetiapineSerotonin 2a (5-HT2a) receptor antagonist
- CycloserineD-alanylalanine synthetase inhibitor
- FluoxetineSerotonin transporter inhibitor
- FluvoxamineSerotonin transporter inhibitor
- Yohimbine
Phase 2 12
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- OxytocinOxytocin receptor agonist
- EmicerfontCorticotropin releasing factor receptor 1 antagonist
- EscitalopramSerotonin transporter inhibitor
- AtomoxetineNorepinephrine transporter inhibitor
- ZiprasidoneSerotonin 2a (5-HT2a) receptor antagonist
- VestipitantNeurokinin 1 receptor antagonist
- TradipitantNeurokinin 1 receptor antagonist
- Icosapent
- BNC-210Neuronal acetylcholine receptor protein alpha-7 subunit negative allosteric modulator
- Fish oilSupplement
- MidomafetamineSodium-dependent dopamine transporter releasing agent
Phase 1 or earlier 4
- AlprazolamGABA-A receptor; anion channel positive allosteric modulator
- ScopolamineMuscarinic acetylcholine receptor M1 antagonist
- VerucerfontCorticotropin releasing factor receptor 1 antagonist
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
How its trials ended
310 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 69 whose ending is known, 57% met their primary endpoint, 4% missed it and 39% stopped early.
- Completed, result not reported15650%
- Ongoing6120%
- Met its primary endpoint3913%
- Status unknown248%
- Stopped: other or unclear155%
- Stopped: enrollment or feasibility52%
- Stopped: sponsor or business decision41%
- Missed its primary endpoint31%
- Stopped: funding21%
- Stopped: lack of efficacy1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA